Within the Medical Cannabis Market , CBD (cannabidiol) holds the largest share, reflecting its broad therapeutic applications and non-psychoactive nature. CBD is widely used for pain management, anxiety, sleep disorders, and epilepsy. Its popularity has been fueled by the approval of Epidiolex and the proliferation of CBD-containing products in health and wellness markets. CBD is available in various forms, including oils, tinctures, capsules, edibles, and topicals.

While CBD dominates, THC (tetrahydrocannabinol) is a significant and growing segment. THC is the psychoactive component of cannabis and is effective for pain, nausea, and appetite stimulation. THC-based products, such as Marinol and Syndros, are approved for chemotherapy-induced nausea and vomiting and AIDS-related anorexia. The medical use of THC is expanding as more patients seek its therapeutic benefits.

Other cannabinoids, such as CBG (cannabigerol), CBN (cannabinol), and THCV (tetrahydrocannabivarin), are gaining attention for their potential therapeutic properties. Research into these minor cannabinoids is still in its early stages, but preliminary studies suggest they may have applications in pain, inflammation, and neurological disorders. As research progresses, the market for these cannabinoids is expected to grow.

The market is also segmented by product type, including oils, tinctures, capsules, topicals, and dried flower. Oils and tinctures are the most popular forms, offering precise dosing and rapid absorption. Capsules provide a convenient, discreet option, while topicals are used for localized pain and inflammation. Dried flower remains a common form for inhalation, though its use is less common in medical settings due to concerns about respiratory health.

The route of administration is another important segmentation, with oral, sublingual, topical, and inhaled products available. The choice of route depends on the condition being treated, patient preference, and the desired onset and duration of action.